New Site Metrix Helps Pharma Inform Clinical Trial Plans
CHICAGO, Illinois, November 1, 2017-KMR Group, a company specializing in biopharmaceutical R&D performance analytics, announces its newest release of Site Metrix Application. Site Metrix provides clinical site performance benchmarks to the biopharma industry. The data is used to help biopharma in the performance evaluation of their sites and to help set realistic site level enrollment plans. Benchmarks are delivered at the country level in order to help those involved with trial placement more effectively plan for their trials.
The enhanced Site Metrix lets users access site level Industry benchmarks in categories such as site start-up, screening, randomization, and IRB metrics. With the updated GridView module and more detailed indications, the flexibility of the data being analyzed can be further customized by a host of measures including phase, year range, site type, and country. Users always can see their own company’s performance side by side with the Industry in the application.
Accessing data based on site level performance has previously been a challenge. The granularity needed by trial planners requires the expertise and breadth of performance information that does not stem from publically available sources. Through KMR Group’s clinical program, detailed site level performance information is available for sponsor companies to assist in all facets of clinical trial planning.
Clinical trial planners need access to information beyond their company’s past performance in order to make more informed decisions about upcoming trials. Evaluating industry data at the trial level, site level, and individual site level are all beneficial for the most comprehensive plans. Site Metrix is just one of a host of online tools KMR Group has developed to benefit the biopharma industry at each stage in the enrollment and trial planning process.
Site Metrix complements KMR Group’s Site Scorecard Application which provides individual site metrics, lists, and ranks for specific named sites. “Our site level information is unparalleled in the industry. With over 650,000 site instances used in our datasets, KMR Group’s site tools provide an unparalleled set of industry performance as well as data flexibility for our clients,” commented Linda Martin, KMR Group President and Founder.
For more information about KMR Group’s Site Metrix or other clinical tools contact:
Lyndsey McKay, Associate Director, Marketing Tel: +1 (312) 795-0400 Email: lmckay [at] kmrgroup.com
About KMR
KMR Group has worked exclusively in biopharmaceutical R&D since the early 1990s. KMR Group specializes in benchmarking, analytics and performance management as well as a developer of on-line analytics tools that enable access to propriety and rich datasets. KMR's clinical platform contains the most reliable source for trial performance, recruitment, and site metrics data, with over 25,000 global clinical trials. Clients depend on these tools to benchmark performance, define recruitment strategies and shape enrollment plans and to identify best performing sites.
Visit our website at https://kmrgroup.com
Follow us on Twitter @KMRGroupInc
KMR Group
150 North Wacker Drive, Suite 1070 • Chicago, Illinois 60606 USA
+1 312-795-0400 • Fax +1 312-795-0491
Copyright © KMR Group 2017 All rights reserved.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
